Acucela Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Seattle WA United States (2002)

Organization Overview

First Clinical Trial
2008
NCT00703183
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Acucela Inc. | VP of Clinical Development, Acucela

Active Ingredients

Drugs in Phase 3 Trials (2)

emixustat (8 trials)

rebamipide (3 trials)

Drugs in Phase 2 Trials (2)

latanoprost (xalatan) (1 trial)

opa-6566 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anetoderma (Phase 2)

Atrophy (Phase 3)

Diabetic Retinopathy (Phase 2)

Dry Eye Syndromes (Phase 3)

Geographic Atrophy (Phase 3)

Glaucoma (Phase 2)

Glaucoma, Open-Angle (Phase 2)

Hypertension (Phase 2)

Keratoconjunctivitis (Phase 2)

Keratoconjunctivitis Sicca (Phase 3)

Macular Degeneration (Phase 3)

Ocular Hypertension (Phase 2)

Retinal Diseases (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 4